GRTX — Galera Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Galera Therapeutics Inc Announces Results Of Phase 3 Roman Trial Of Avasopasem For Radiotherapy-Induced Severe Oral Mucositis
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
U.S. STOCKS ON THE MOVE-Virios, McAfee, Perrigo
Galera Therapeutics up as pancreatic cancer therapy improves overall survival
Brief: Galera Announces Final Results From Pancreatic Cancer Trial Showing Improvements On All Efficacy Parameters
Brief: Galera Says Entered Manufacturing Services Agreement With Patheon Manufacturing Services
Galera Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Galera Therapeutics Inc Posts Q2 Loss Per Share $0.88
Galera Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview
Brief: Galera Announces First Patient Dosed With GC4711 In Phase 2B Greco-2 Trial In Patients With Pancreatic Cancer
Galera Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Galera Reports Q1 Loss Per Share Of $0.75
Galera Therapeutics soars on positive pancreatic cancer trial update
U.S. STOCKS ON THE MOVE-ServiceNow, Apple, Overstock.com
U.S. STOCKS ON THE MOVE-Caterpillar, Facebook, Ford
Brief: Galera Announces Updated Data From Its Randomized, Multicenter, Placebo-Controlled Trial In Patients With Pancreatic Cancer
Brief: Galera Therapeutics Reports Q4 And FY2020 Financial Results
Brief: Galera Therapeutics Inc Files For Mixed Shelf Of Up To $200 Mln
Brief: Galera Therapeutics Reports Q3 Loss Per Share $0.69